MCID: CRC014
MIFTS: 48

Carcinoid Tumors, Intestinal malady

Categories: Genetic diseases (common), Gastrointestinal diseases, Cancer diseases

Aliases & Classifications for Carcinoid Tumors, Intestinal

About this section

Aliases & Descriptions for Carcinoid Tumors, Intestinal:

Name: Carcinoid Tumors, Intestinal 49 11
Gastrointestinal Carcinoid Tumor 67 65
Argentaffinoma 67 65
Carcinoid Tumor No Icd-O Subtype 65
Carcinoid Tumor of Intestine 65
 
Copper Toxicosis, Idiopathic 65
Intestinal Carcinoid Tumor 67
Carcinoid Tumor 65
Carcinoid 67
Ict 67

Characteristics:

HPO:

61
carcinoid tumors, intestinal:
Inheritance: autosomal dominant inheritance


Classifications:



External Ids:

OMIM49 114900
MedGen34 C0349535
MeSH36 D002276
UMLS65 C0349535, C0600176, C0007095 C0334299, C0220620, C1859088, more

Summaries for Carcinoid Tumors, Intestinal

About this section
UniProtKB/Swiss-Prot:67 Intestinal carcinoid tumor: A yellow, well-differentiated, circumscribed tumor that arises from enterochromaffin cells in the small intestine or, less frequently, in other parts of the gastrointestinal tract.

MalaCards based summary: Carcinoid Tumors, Intestinal, also known as gastrointestinal carcinoid tumor, is related to tubular adenocarcinoma and carcinoid syndrome, and has symptoms including intestinal carcinoid An important gene associated with Carcinoid Tumors, Intestinal is SDHD (Succinate Dehydrogenase Complex Subunit D), and among its related pathways are Citrate cycle (TCA cycle) and Thyroid hormone signaling pathway. Affiliated tissues include small intestine, lung and breast, and related mouse phenotypes are endocrine/exocrine gland and tumorigenesis.

Description from OMIM:49 114900

Related Diseases for Carcinoid Tumors, Intestinal

About this section

Diseases related to Carcinoid Tumors, Intestinal via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 289)
idRelated DiseaseScoreTop Affiliating Genes
1tubular adenocarcinoma28.6CTNNB1, NOTCH1
2carcinoid syndrome12.4
3goblet cell carcinoid12.2
4carcinoid tumor and carcinoid syndrome12.2
5appendix carcinoid tumor12.1
6duodenal carcinoid syndrome11.9
7bronchial adenomas/carcinoids childhood11.9
8small intestine carcinoid neuroendocrine tumor11.8
9carcinoid tumor childhood11.8
10somatostatinoma11.3
11bronchial endocrine tumor11.0
12hereditary neuroendocrine tumor of small intestine10.8
13serotonin syndrome10.8
14thymic endocrine tumor10.8
15primary hepatic neuroendocrine carcinoma10.8
16neuroendocrine tumor10.7
17diffuse idiopathic pulmonary neuroendocrine cell hyperplasia10.5
18pellagra10.4
19multiple endocrine neoplasia 110.4
20hepatitis10.4
21cushing's syndrome10.3
22teratoma10.3
23heart disease10.3
24gastritis10.2
25prostate leiomyosarcoma10.2ENO2, SDHD
26multiple endocrine neoplasia10.2
27pancreatitis10.2
28adenocarcinoma10.2
29atrophic gastritis10.2
30seminal vesicle adenocarcinoma10.1ENO2, NKX2-1
31zollinger-ellison syndrome10.1
32diffuse pulmonary fibrosis10.1ENO2, NKX2-1
33pernicious anemia10.1
34mature teratoma10.1
35adenoma10.1
36non-invasive bladder papillary urothelial neoplasm10.1ENO2, NKX2-1
37meckel's diverticulum10.1
38cervical large cell neuroendocrine carcinoma10.1ENO2, NKX2-1
39thyroiditis10.1
40melas syndrome10.0ENO2, NKX2-1
41small cell carcinoma10.0
42diarrhea10.0
43duodenitis10.0
44horseshoe kidney10.0
45organ system cancer10.0ENO2, NKX2-1
46cystic teratoma10.0
47filariasis10.0
48pheochromocytoma10.0
49gastrinoma10.0
50medullary thyroid carcinoma, familial9.9ENO2, NKX2-1

Graphical network of the top 20 diseases related to Carcinoid Tumors, Intestinal:



Diseases related to carcinoid tumors, intestinal

Symptoms for Carcinoid Tumors, Intestinal

About this section

Symptoms by clinical synopsis from OMIM:

114900

Clinical features from OMIM:

114900

HPO human phenotypes related to Carcinoid Tumors, Intestinal:

id Description Frequency HPO Source Accession
1 intestinal carcinoid HP:0006723

Drugs & Therapeutics for Carcinoid Tumors, Intestinal

About this section

Drugs for Carcinoid Tumors, Intestinal (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 157)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Oxaliplatinapproved, investigationalPhase 4, Phase 1132261825-94-35310940, 9887054, 6857599, 43805, 6857599, 9887054
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
 
Oxalatoplatin
Oxalatoplatinum
Oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
2
DiazoxideapprovedPhase 421364-98-73019
Synonyms:
2H-1,2, 4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide
2H-1,2,4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide
364-98-7
7-Chloro-3-methyl-1lambda~4~,2,4-benzothiadiazin-1-ol 1-oxide
7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido
7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido [Italian]
7-chloro-3-methyl-4H-1
AC1L1EZN
Aroglycem
BPBio1_000016
BRD-K73109821-001-05-2
BSPBio_000014
BSPBio_001307
BSPBio_002290
Bio1_000036
Bio1_000525
Bio1_001014
Bio2_000027
Bio2_000507
C06949
C8H7ClN2O2S
CAS-364-98-7
CBiol_001750
CHEBI:4495
CHEMBL181
CID3019
CPD000058392
D 9035
D00294
D003981
D9035_SIGMA
DB01119
Diazossido
Diazossido [DCIT]
Diazossido [Italian]
Diazoxide
Diazoxide (JAN/USP/INN)
Diazoxide [USAN:INN:BAN]
Diazoxido
Diazoxido [INN-Spanish]
Diazoxidum
Diazoxidum [INN-Latin]
Dizoxide
EINECS 206-668-1
EU-0100404
Eudemine
HMS1361B09
HMS1568A16
HMS1791B09
HMS1922L22
HMS1989B09
HMS2051P20
HMS2089L04
HMS2093N12
Hyperstat
Hyperstat (TN)
Hypertonalum
I06-2041
 
IDI1_033777
KBio2_000027
KBio2_002595
KBio2_005163
KBio3_000053
KBio3_000054
KBio3_001510
KBioGR_000027
KBioGR_001776
KBioSS_000027
LS-40410
Lopac-D-9035
Lopac0_000404
MLS000028459
MLS001076071
MolPort-003-666-772
MolPort-003-941-186
Mutabase
NCGC00015380-01
NCGC00015380-02
NCGC00015380-03
NCGC00015380-05
NCGC00015380-12
NCGC00024907-01
NCGC00024907-02
NCGC00024907-03
NCGC00024907-04
NCGC00024907-05
NCGC00024907-06
NCGC00024907-07
NCGC00024907-08
NSC 64198
NSC 76130
NSC-64198
NSC64198
NSC76130
Prestwick0_000087
Prestwick1_000087
Prestwick2_000087
Prestwick3_000087
Prestwick_163
Proglicem
Proglycem
SAM001246872
SMR000058392
SPBio_001953
SPECTRUM2300206
SRG 95213
SRG-95213
Sch 6783
Sch-6783
Spectrum3_000735
Spectrum4_001248
Tocris-0964
UNII-O5CB12L4FN
VU0239714-6
ZINC03872277
diazoxide
nchembio.150-comp49
nchembio.476-comp10
3Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 13572
4insulinPhase 44278
5Vasodilator AgentsPhase 42926
6Insulin, Globin ZincPhase 44278
7Antihypertensive AgentsPhase 43618
8ColaNutraceuticalPhase 4, Phase 3, Phase 1, Phase 21768
9
Dexamethasoneapproved, investigationalPhase 3, Phase 2190950-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Baycadron
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
 
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone acetate
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone sodium phosphate
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamethsone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
Ozurdex
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
10
Fentanylapproved, illicit, investigationalPhase 3705437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Abstral
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl - Novaplus
Fentanyl Citrate
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Lazanda
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Subsys
UNII-UF599785JZ
fentanyl
11
Octreotideapproved, investigationalPhase 3, Phase 2, Phase 119883150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
 
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Ocphyl
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide acetate
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatin
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
12
OndansetronapprovedPhase 328599614-02-54595
Synonyms:
(RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one
1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one
103639-04-9 (mono-hydrochloride dihydrate)
108303-49-7
116002-70-1
9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
99614-01-4 (mono-hydrochloride)
99614-02-5
AB00373674
AC1L1IIM
AKOS000599484
Apo-ondansetron
BAS 00717177
BPBio1_001118
BRD-A19736161-001-01-8
BRD-A19736161-003-03-0
BRN 3622981
BSPBio_001016
C07325
C18H19N3O
CBDivE_008994
CHEMBL46
CID4595
CPD001307702
D00456
DB00904
DESMETHYLONDANSETRON
GR 38032
GR 38032X
GR-38032F
GR38032F
HMS2090H16
I06-0687
I06-1329
L000456
 
LS-172305
LS-51878
MolPort-001-944-253
NCI60_022780
Novo-ondansetron
Ondansetron
Ondansetron (JAN/USP/INN)
Ondansetron Hydrochloride
Ondansetron [USAN:INN:BAN]
Ondansetron hydrochloride dihydrate
Ondansetron, (+,-)-Isomer
Oprea1_435466
Oprea1_852372
PHL-ondansetron
PMS-ondansetron
Prestwick0_001058
Prestwick1_001058
Prestwick2_001058
Prestwick3_001058
Ratio-ondansetron
SAM002589958
SN-307
SPBio_002938
STK370548
STOCK4S-10990
Sandoz ondansetron
TL8006071
TimTec1_001750
UNII-4AF302ESOS
ZOFRAN IN PLASTIC CONTAINER
Zofran
Zofran ODT
Zofran ODT (TN)
Zofran odt
Zophren
Zudan
Zuplenz
ondansetron
ondansetron (Zofran)
13Dexamethasone acetatePhase 3, Phase 219091177-87-3
14glucocorticoidsPhase 33896
15Antipsychotic AgentsPhase 32130
16HIV Protease InhibitorsPhase 34558
17BB 1101Phase 3, Phase 21909
18Dermatologic AgentsPhase 34555
19Dexamethasone 21-phosphatePhase 3, Phase 21909
20
SerotoninPhase 3, Phase 2314750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
21Serotonin AntagonistsPhase 3, Phase 21175
22Tranquilizing AgentsPhase 33597
23Anti-Infective AgentsPhase 3, Phase 2, Phase 117220
24Serotonin AgentsPhase 3, Phase 22668
25AntipruriticsPhase 3619
26Protease InhibitorsPhase 34558
27Psychotropic DrugsPhase 35501
28Neurotransmitter AgentsPhase 3, Phase 214795
29Immunologic FactorsPhase 3, Phase 2, Phase 118483
30Gastrointestinal AgentsPhase 3, Phase 1, Phase 26401
31AnalgesicsPhase 39358
32Analgesics, OpioidPhase 32304
33
SomatostatinPhase 3, Phase 1, Phase 215351110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
34Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 39988
35Anti-Inflammatory AgentsPhase 38478
36Hormone AntagonistsPhase 310002
37HormonesPhase 311748
38AnestheticsPhase 37385
39Antineoplastic Agents, HormonalPhase 3, Phase 1, Phase 24256
40Peripheral Nervous System AgentsPhase 3, Phase 218510
41Anesthetics, GeneralPhase 32274
42Anti-Anxiety AgentsPhase 31529
43pancreatic polypeptidePhase 3, Phase 2, Phase 120
44NarcoticsPhase 32709
45Anesthetics, IntravenousPhase 31943
46Central Nervous System DepressantsPhase 310016
47AntiemeticsPhase 33213
48Pharmaceutical SolutionsPhase 37004
49interferonsPhase 3, Phase 2, Phase 11930
50Antiviral AgentsPhase 3, Phase 28071

Interventional clinical trials:

(show top 50)    (show all 92)
idNameStatusNCT IDPhase
1Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal CancerRecruitingNCT00274885Phase 4
2Pasireotide Treatment for Neuroendocrine TumorEnrolling by invitationNCT02779257Phase 4
3TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)CompletedNCT01677910Phase 3
4Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid DiseaseCompletedNCT00690430Phase 3
5Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
6Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper AbdomenCompletedNCT00016380Phase 3
7Telotristat Etiprate for Carcinoid Syndrome TherapyCompletedNCT02063659Phase 3
8177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETsRecruitingNCT01842165Phase 3
9A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid TumoursActive, not recruitingNCT01578239Phase 3
10[68 Ga]-DOTANOC PET/CT in GEP-NETsNot yet recruitingNCT02608203Phase 2, Phase 3
11Randomized Phase III of PRRT Versus InterferonWithdrawnNCT01860742Phase 3
12Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel ObstructionCompletedNCT00004911Phase 1, Phase 2
13Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal ObstructionCompletedNCT00004910Phase 1, Phase 2
14Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal CancerCompletedNCT00005049Phase 2
1568Ga-OPS202 Study for Diagnostic Imaging of GEP NETCompletedNCT02162446Phase 1, Phase 2
16Study of LX1606 in Subjects With Symptomatic Carcinoid SyndromeCompletedNCT01104415Phase 2
17Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver CancerCompletedNCT00096083Phase 2
18The Safety and Efficacy of CPTK787/ZK222584 in Patients With Metastatic Neuroendocrine TumorsCompletedNCT00627198Phase 2
19Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide TherapyCompletedNCT00853047Phase 2
20Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver MetastasesCompletedNCT01290536Phase 2
21Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT01154452Phase 1, Phase 2
22A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...CompletedNCT00923481Phase 2
23TheraSphere for the Treatment of Liver MetastasesCompletedNCT00511862Phase 2
24Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine TumorsRecruitingNCT02078843Phase 1, Phase 2
25Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine TumorsRecruitingNCT02736500Phase 1, Phase 2
26Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine TumorsRecruitingNCT02489604Phase 2
27A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine TumorRecruitingNCT01994213Phase 2
28177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine TumorsRecruitingNCT02736448Phase 2
29Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mgRecruitingNCT02651987Phase 2
30Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NETRecruitingNCT02231762Phase 2
31Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions)RecruitingNCT02568267Phase 2
32Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal CancerRecruitingNCT00445965Phase 2
33A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine CarcinomasRecruitingNCT02215447Phase 2
34Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by SurgeryRecruitingNCT02595424Phase 2
35Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic OriginRecruitingNCT02687958Phase 2
36The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid CancerRecruitingNCT01739634Phase 1, Phase 2
37PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCERRecruitingNCT01037790Phase 2
38Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract CancerActive, not recruitingNCT00019474Phase 2
39Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)Active, not recruitingNCT01253161Phase 2
40Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid TumorsActive, not recruitingNCT01177007Phase 2
41Vandetanib to Treat Children and Adolescents With Medullary Thyroid CancerActive, not recruitingNCT00514046Phase 1, Phase 2
42A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.Active, not recruitingNCT00378482Phase 2
43YF476 and Type II Gastric CarcinoidsEnrolling by invitationNCT02454075Phase 2
44Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours StudyNot yet recruitingNCT02358356Phase 2
45Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPSC001 in GEP NETsNot yet recruitingNCT02592707Phase 1, Phase 2
46Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal CancerSuspendedNCT01769222Phase 1, Phase 2
47Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal CancerTerminatedNCT00903396Phase 2
48MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.TerminatedNCT00147550Phase 1, Phase 2
49Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal CancerCompletedNCT00003427Phase 1
507-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1

Search NIH Clinical Center for Carcinoid Tumors, Intestinal

Genetic Tests for Carcinoid Tumors, Intestinal

About this section

Anatomical Context for Carcinoid Tumors, Intestinal

About this section

MalaCards organs/tissues related to Carcinoid Tumors, Intestinal:

33
Small intestine, Lung, Breast, Liver, Thyroid, Prostate, Colon

Animal Models for Carcinoid Tumors, Intestinal or affiliated genes

About this section

MGI Mouse Phenotypes related to Carcinoid Tumors, Intestinal:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053798.4CTNNB1, NKX2-1, NOTCH1, SDHD
2MP:00020068.3CTNNB1, NKX2-1, NOTCH1, SDHD
3MP:00028738.3CTNNB1, NKX2-1, NOTCH1, SDHD
4MP:00053888.1CTNNB1, ENO2, NKX2-1, NOTCH1
5MP:00036317.5CTNNB1, ENO2, NKX2-1, NOTCH1, SDHD
6MP:00053787.5CTNNB1, ENO2, NKX2-1, NOTCH1, SDHD
7MP:00053847.4CTNNB1, ENO2, NKX2-1, NOTCH1, SDHD

Publications for Carcinoid Tumors, Intestinal

About this section

Variations for Carcinoid Tumors, Intestinal

About this section

Clinvar genetic disease variations for Carcinoid Tumors, Intestinal:

5
id Gene Variation Type Significance SNP ID Assembly Location
1SDHDNM_003002.3(SDHD): c.34G> A (p.Gly12Ser)single nucleotide variantPathogenicrs34677591GRCh37Chr 11, 111957665: 111957665

Expression for genes affiliated with Carcinoid Tumors, Intestinal

About this section
Search GEO for disease gene expression data for Carcinoid Tumors, Intestinal.

Pathways for genes affiliated with Carcinoid Tumors, Intestinal

About this section

GO Terms for genes affiliated with Carcinoid Tumors, Intestinal

About this section

Biological processes related to Carcinoid Tumors, Intestinal according to GeneCards Suite gene sharing:

(show all 22)
idNameGO IDScoreTop Affiliating Genes
1oligodendrocyte differentiationGO:00487099.9NKX2-1, NOTCH1
2positive regulation of endothelial cell differentiationGO:00456039.6CTNNB1, NOTCH1
3regulation of neurogenesisGO:00507679.6CTNNB1, NOTCH1
4hair follicle morphogenesisGO:00310699.6CTNNB1, NOTCH1
5negative regulation of oligodendrocyte differentiationGO:00487159.5CTNNB1, NOTCH1
6embryonic hindlimb morphogenesisGO:00351169.5CTNNB1, NOTCH1
7cell fate specificationGO:00017089.5CTNNB1, NOTCH1
8regulation of gene expressionGO:00104689.5CTNNB1, NOTCH1
9neuron differentiationGO:00301829.5CTNNB1, NOTCH1
10in utero embryonic developmentGO:00017019.4CTNNB1, NOTCH1
11epithelial to mesenchymal transitionGO:00018379.4CTNNB1, NOTCH1
12neuron migrationGO:00017649.4CTNNB1, NKX2-1
13positive regulation of apoptotic processGO:00430659.4CTNNB1, NOTCH1
14response to lipopolysaccharideGO:00324969.2NKX2-1, NOTCH1
15forebrain developmentGO:00309009.0CTNNB1, NKX2-1, NOTCH1
16liver developmentGO:00018899.0CTNNB1, NOTCH1
17regulation of cell proliferationGO:00421279.0CTNNB1, NOTCH1
18regulation of transcription from RNA polymerase II promoterGO:00063578.8CTNNB1, NKX2-1, NOTCH1
19negative regulation of transcription, DNA-templatedGO:00458928.8CTNNB1, NKX2-1, NOTCH1
20positive regulation of neuroblast proliferationGO:00020528.7CTNNB1, NOTCH1
21regulation of transcription, DNA-templatedGO:00063558.7CTNNB1, NKX2-1, NOTCH1
22lung developmentGO:00303248.6CTNNB1, NKX2-1, NOTCH1

Molecular functions related to Carcinoid Tumors, Intestinal according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1transcription factor activity, sequence-specific DNA bindingGO:00037009.3NKX2-1, NOTCH1

Sources for Carcinoid Tumors, Intestinal

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet